Drugs / 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04100772 | May 2020 → Jun 2021 | pneumococcal infection | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07017777 | Nov 2025 → Feb 2027 expected | pneumococcal infection | CanSino Biologics Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT04841369 | Apr 2021 → Mar 2022 | pneumococcal infection | CanSino Biologics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT） | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04841369 ↗ |
| Known as | PCV13i | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07017777 ↗ |
| Modality | Vaccine | “PCV13i vaccine” NCT04100772 ↗ |
| Route | Intramuscular | “0.5mL,Intramuscular” NCT04841369 ↗ |